The Promising Therapeutic Potential of Oligonucleotides for Pulmonary Fibrotic Diseases

References

• Gbdcrd C, Kendrick PJ, Paulson KR. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med. 2020 Jun;8(6):585–596.
   PubMed Web of Science ®Google Scholar
• Brown KK, Martinez FJ, Walsh SLF, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020 Jun;55(6):2000085.
   PubMed Web of Science ®Google Scholar
• Interstitial Lung Disease American Lung Association 2022. Available from: https://www.lung.org/lung-health-diseases/lung-disease-lookup/interstitial-lung-disease
   Google Scholar
• Bazdyrev E, Rusina P, Panova M, et al. Lung Fibrosis after COVID-19: treatment Prospects. Pharmaceuticals (Basel). 2021 Aug 17;14(8):807.
   PubMedGoogle Scholar
• Laporta Hernandez R, Aguilar Perez M, Lázaro Carrasco MT, et al. Lung transplantation in idiopathic pulmonary fibrosis. Medical sciences. (Basel Switzerland): 2018 Aug 23;6(3):68.
   Google Scholar
• Strens D, Bondue B, Dahlqvist C, et al. Long-term tolerability of real-life use of antifibrotic agents (AFA) in Idiopathic Pulmonary Fibrosis (IPF). Eur Respir J. 2021;58(suppl 65):A465.
   Google Scholar
• Ruigrok MJR, Frijlink HW, Hinrichs WLJ. Pulmonary administration of small interfering RNA: the route to go? J Control Release. 2016 Aug 10;235:14–23.
   PubMed Web of Science ®Google Scholar
• Maher JM, Zhang R, Palanisamy G, et al. Lung-restricted ALK5 inhibition avoids systemic toxicities associated with TGFβ pathway inhibition. Toxicol Appl Pharmacol. 2022 Mar 1;438:115905.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017 Oct 20;3(1):17074.
   PubMedGoogle Scholar
• Desai TJ, Brownfield DG, Krasnow MA. Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature. 2014 Mar 13;507(7491):190–194.
   PubMed Web of Science ®Google Scholar
• Glasser SW, Hardie WD, Hagood JS. Pathogenesis of Interstitial Lung Disease in Children and Adults. Pediatr Allergy Immunol Pulmonol. 2010 Mar;23(1):9–14.
   PubMed Web of Science ®Google Scholar
• Chen H, Qu J, Huang X, et al. Mechanosensing by the alpha6-integrin confers an invasive fibroblast phenotype and mediates lung fibrosis. Nat Commun. 2016 Aug 18;7(1):12564.
   PubMedGoogle Scholar
• Uhal BD, Joshi I, Hughes WF, et al. Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am J Physiol. 1998 Dec;275(6):L1192–9.
   PubMedGoogle Scholar
• Zhang L, Wang Y, Wu G, et al. Macrophages: friend or foe in idiopathic pulmonary fibrosis? Respir Res. 2018 Sep 6;19(1):170.
   PubMedGoogle Scholar
• Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013 Jun;1(4):309–317.
   PubMed Web of Science ®Google Scholar
• NAEPP: National Asthma Education and Prevention Program Tepotdamoa. Expert panel Report 3: guidelines for the diagnosis and management of asthma. Bethestda MD: National Heart, Lung, and Blood Institute (US).; 2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK7232/.
   Google Scholar
• Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy. 2012 May;42(5):650–658.
   PubMed Web of Science ®Google Scholar
• Kumar S, Jeong Y, Ashraf MU, et al. Dendritic cell-mediated Th2 Immunity and immune disorders. Int J Mol Sci. 2019 May 1;20(9):2159.
   PubMed Web of Science ®Google Scholar
• Leon B, Ballesteros-Tato A. Modulating Th2 Cell Immunity for the treatment of asthma. Front Immunol. 2021;12:637948.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled Asthma. N Engl J Med. 2021 May 13;384(19):1800–1809.
   PubMed Web of Science ®Google Scholar
• Chen Y, Dales R, Krewski D, et al. Increased effects of smoking and obesity on asthma among female Canadians: the national population health survey, 1994-1995. Am J Epidemiol. 1999 Aug 1;150(3):255–262.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017 May 13;389(10082):1931–1940.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006 Apr;3(2):180–184.
   PubMedGoogle Scholar
• Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012 Apr 7;379(9823):1341–1351.
   PubMed Web of Science ®Google Scholar
• Moll M, Sakornsakolpat P, Shrine N, et al. Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts. Lancet Respir Med. 2020 Jul;8(7):696–708.
   PubMed Web of Science ®Google Scholar
• Chen Q, Shen Y, Zheng J. A review of cystic fibrosis: basic and clinical aspects. Animal Model Exp Med. 2021 Sep;4(3): 220–232.
   PubMedGoogle Scholar
• Elborn JS. Cystic fibrosis. Lancet. 2016 Nov 19;388(10059):2519–2531.
   PubMed Web of Science ®Google Scholar
• Giron Moreno RM, Garcia-Clemente M, Diab-Caceres L, et al. Treatment of Pulmonary Disease of Cystic Fibrosis: a Comprehensive Review. Antibiotics (Basel). 2021 Apr 23;10(5):486.
   PubMed Web of Science ®Google Scholar
• Bose SJ, Krainer G, Drs N, et al. Towards next generation therapies for cystic fibrosis: folding, function and pharmacology of CFTR. J Cyst Fibros. 2020 Mar;19 Suppl 1:S25–S32.
   PubMed Web of Science ®Google Scholar
• Moore PJ, Tarran R. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease. Expert Opin Ther Targets. 2018 Aug;22(8):687–701.
   PubMed Web of Science ®Google Scholar
• Darquenne C. Deposition Mechanisms. J Aerosol Med Pulm Drug Deliv. 2020;33(4):181–185.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Lam JK, Leung SW, et al. Delivery of RNAi Therapeutics to the Airways-From Bench to Bedside. Molecules. 2016 Sep 20;21(9):1249.
   PubMed Web of Science ®Google Scholar
• Bost JP, Barriga H, Holme MN, et al. Delivery of oligonucleotide therapeutics: chemical modifications, lipid nanoparticles, and extracellular vesicles. ACS Nano. 2021 Sep 28;15(9):13993–14021.
   PubMed Web of Science ®Google Scholar
• Egli M, Manoharan M. Re-Engineering RNA molecules into therapeutic agents. Acc Chem Res. 2019 Apr 16;52(4):1036–1047.
   PubMed Web of Science ®Google Scholar
• Kandasamy P, Liu Y, Aduda V, et al. Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS. Nucleic Acids Res. 2022 Feb 2;50(10):5401–5423.
   PubMed Web of Science ®Google Scholar
• Iwamoto N, Butler DCD, Svrzikapa N, et al. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat Biotechnol. 2017 Sep;35(9):845–851.
   PubMed Web of Science ®Google Scholar
• Karras JG, Crosby JR, Guha M, et al. Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice. Am J Respir Cell Mol Biol. 2007 Mar;36(3):276–285.
   PubMed Web of Science ®Google Scholar
• Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017 Mar;35(3):238–248.
   PubMed Web of Science ®Google Scholar
• Seth PP, Siwkowski A, Allerson CR, et al. Short antisense oligonucleotides with novel 2′−4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem. 2009 JAN 08;52(1):10–13.
   PubMed Web of Science ®Google Scholar
• Nur SM, Al Amin M, Alam R, et al. An in silico approach to design potential siRNA molecules for ICP22 (US1) gene silencing of different strains of human herpes simplex 1. J Young Pharm. 2013 Jun;5(2):46–49.
   PubMedGoogle Scholar
• Hong D, Kurzrock R, Kim Y, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015 Nov 18;7(314):314ra185.
   PubMed Web of Science ®Google Scholar
• Ionis Pharmaceuticals I A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis. 2018. https://ClinicalTrials.gov/show/NCT03647228
   Google Scholar
• Sutharsan S, Fischer R, Gleiber W, et al. Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION-827359, an Antisense Oligonucleotide Inhibitor of ENaC, in Healthy Volunteers and Patients with Cystic Fibrosis: a Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2a Study. Healthy Volunteers and Patients with Cystic Fibrosis: A Double-Blind, Placebo-Controlled, Dose-Escalation, Phase.1.
   Google Scholar
• Siwkowski AM, Madge LA, Koo S, et al. Effects of antisense oligonucleotide-mediated depletion of tumor necrosis factor (TNF) receptor 1-associated death domain protein on TNF-induced gene expression. Mol Pharmacol. 2004 Sep;66(3):572–579.
   PubMed Web of Science ®Google Scholar
• Crosby JR, Guha M, Tung D, et al. Inhaled CD86 antisense oligonucleotide suppresses pulmonary inflammation and airway hyper-responsiveness in allergic mice. J Pharmacol Exp Ther. 2007 Jun;321(3):938–946.
   PubMed Web of Science ®Google Scholar
• Daniel C, Takabatake Y, Mizui M, et al. Antisense oligonucleotides against thrombospondin-1 inhibit activation of tgf-beta in fibrotic renal disease in the rat in vivo. Am J Pathol. 2003 Sep;163(3):1185–1192.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Fukuhara D, Akase D, et al. siRNA Seed Region Is Divided into Two Functionally Different Domains in RNA Interference in Response to 2’-OMe Modifications. ACS Omega. 2022 Jan 18;7(2):2398–2410.
   PubMed Web of Science ®Google Scholar
• Oh SY, Ju Y, Park H. A highly effective and long-lasting inhibition of miRNAs with PNA-based antisense oligonucleotides. Mol Cells. 2009 Oct 31;28(4):341–345.
   PubMed Web of Science ®Google Scholar
• Oren YS, Irony-Tur Sinai M, Golec A, et al. Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation. J Cyst Fibros. 2021 [2021 Oct 01];20(5):865–875.
   PubMed Web of Science ®Google Scholar
• Bhindi R, Fahmy RG, Lowe HC, et al. Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am J Pathol. 2007;171(4):1079–1088.
   PubMed Web of Science ®Google Scholar
• Greulich T, Hohlfeld JM, Neuser P, et al. A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial. Respir Res. 2018;19(1):55–55.
   PubMedGoogle Scholar
• Calton M, Kotterman M, Schmitt C, et al. A10. A010 NOVEL DISCOVERIES IN LUNG BIOLOGY. In: Identification and Characterization of a Novel AAV Capsid and Product for the Treatment of Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2021;A1043–A1043.
   Google Scholar
• 4D-710 in Adult Patients With Cystic Fibrosis. https://ClinicalTrials.gov/show/NCT05248230.
   Google Scholar
• Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis. https://ClinicalTrials.gov/show/NCT03375047.
   Google Scholar
• CAP-1002 in Severe COVID-19 Disease. https://ClinicalTrials.gov/show/NCT04338347.
   Google Scholar
• Haque AKMA, Dewerth A, Antony JS, et al. Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis. Sci Rep. 2018 Nov 13;8(1):16776.
   PubMedGoogle Scholar
• Capel V, Vllasaliu D, Watts P, et al. Water-soluble substituted chitosan derivatives as technology platform for inhalation delivery of siRNA. Drug Deliv. 2018 Jan 01;25(1):644–653.
   PubMed Web of Science ®Google Scholar
• Xie Y, Kim NH, Nadithe V, et al. Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. J Control Release. 2016 May 10;229:120–129.
   PubMed Web of Science ®Google Scholar
• Agu RU, Ugwoke MI, Armand M, et al. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res. 2001;2(4):198–209.
   PubMed Web of Science ®Google Scholar
• Sharma K, Somavarapu S, Colombani A, et al. Crosslinked chitosan nanoparticle formulations for delivery from pressurized metered dose inhalers. Eur J Pharm Biopharm. 2012 May;81(1):74–81.
   PubMed Web of Science ®Google Scholar
• Sharma K, Somavarapu S, Colombani A, et al. Nebulised siRNA encapsulated crosslinked chitosan nanoparticles for pulmonary delivery. Int J Pharm. 2013 Oct 15;455(1–2):241–247.
   PubMed Web of Science ®Google Scholar
• Mainelis G, Seshadri S, Garbuzenko OB, et al. Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice. J Aerosol Med Pulm Drug Deliv. 2013 Dec;26(6):345–354.
   PubMed Web of Science ®Google Scholar
• Aich J, Mabalirajan U, Ahmad T, et al. Loss-of-function of inositol polyphosphate-4-phosphatase reversibly increases the severity of allergic airway inflammation. Nat Commun. 2012 Jun 6;3(1):877.
   PubMedGoogle Scholar
• Youngren-Ortiz SR, Gandhi NS, Espana-Serrano L, et al. Aerosol Delivery of siRNA to the Lungs. Part 1: rationale for Gene Delivery Systems. Kona. 2016 Feb 28;33:63–85.
   PubMedGoogle Scholar
• Zhang X, Shan P, Jiang D, et al. Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J Biol Chem. 2004 Mar 12;279(11):10677–10684.
   PubMed Web of Science ®Google Scholar
• Bitko V, Musiyenko A, Shulyayeva O, et al. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med. 2005 Jan;11(1):50–55.
   PubMed Web of Science ®Google Scholar
• Senoo T, Hattori N, Tanimoto T, et al. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax. 2010 Apr;65(4):334–340.
   PubMed Web of Science ®Google Scholar
• Heyder J, Gebhart J, Rudolf G, et al. Deposition of particles in the human respiratory tract in the size range 0.005–15 μm. J Aerosol Sci. 1986 Jan 01;17(5):811–825.
   Web of Science ®Google Scholar
• Illum L. Nasal drug delivery–possibilities, problems and solutions. J Control Release. 2003 Feb 21;87(1–3):187–198.
   PubMed Web of Science ®Google Scholar
• DeVincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 2008 Mar;77(3):225–231.
   PubMed Web of Science ®Google Scholar
• Kim J, Jeon S, Kang SJ, et al. Lung-targeted delivery of TGF-β antisense oligonucleotides to treat pulmonary fibrosis. J Control Release. 2020 Jun 10;322:108–121.
   PubMed Web of Science ®Google Scholar
• Zhou J, Li D, Wen H, et al. Inter-molecular β-sheet structure facilitates lung-targeting siRNA delivery. Sci Rep. 2016 Mar 9;6(1):22731.
   PubMedGoogle Scholar
• Polach KJ, Matar M, Rice J, et al. Delivery of siRNA to the mouse lung via a functionalized lipopolyamine. Mol Ther. 2012 Jan;20(1):91–100.
   PubMed Web of Science ®Google Scholar
• Yan Y, Zhou K, Xiong H, et al. Aerosol delivery of stabilized polyester-siRNA nanoparticles to silence gene expression in orthotopic lung tumors. Biomaterials. 2017 Feb;118:84–93.
   PubMed Web of Science ®Google Scholar
• Garbuzenko OB, Saad M, Betigeri S, et al. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm Res. 2009 Feb;26(2):382–394.
   PubMed Web of Science ®Google Scholar
• Lam JK, Liang W, Chan HK. Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev. 2012 Jan;64(1):1–15.
   PubMed Web of Science ®Google Scholar
• Bivas-Benita M, Zwier R, Junginger HE, et al. Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm. 2005 Oct;61(3):214–218.
   PubMed Web of Science ®Google Scholar
• Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev. 2006 Oct 31;58(9–10):1030–1060.
   PubMed Web of Science ®Google Scholar
• Perl M, Chung CS, Lomas-Neira J, et al. Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis. Am J Pathol. 2005 Dec;167(6):1545–1559.
   PubMed Web of Science ®Google Scholar
• Xie Y, Merkel OM. Pulmonary Delivery of siRNA via Polymeric Vectors as Therapies of Asthma. Arch Pharm (Weinheim). 2015 Oct;348(10):681–688.
   PubMed Web of Science ®Google Scholar
• Koping-Hoggard M, Issa MM, Kohler T, et al. A miniaturized nebulization catheter for improved gene delivery to the mouse lung. J Gene Med. 2005 Sep;7(9):1215–1222.
   PubMed Web of Science ®Google Scholar
• Nielsen EJ, Nielsen JM, Becker D, et al. Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles. Pharm Res. 2010 Dec;27(12):2520–2527.
   PubMed Web of Science ®Google Scholar
• Sinsuebpol C, Chatchawalsaisin J, Kulvanich P. Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery. Drug Des Devel Ther. 2013;7:861–873.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Almazi JG, Ong HX, et al. Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract. Int J Mol Sci. 2022 Feb 22;23(5):2408.
   Google Scholar
• Li Q, Chan C, Peterson N, et al. Engineering caveolae-targeted lipid nanoparticles to deliver mRNA to the lungs. ACS Chem Biol. 2020 Apr 17;15(4):830–836.
   PubMed Web of Science ®Google Scholar
• Sigurdsson HH, Kirch J, Lehr CM. Mucus as a barrier to lipophilic drugs. Int J Pharm. 2013 Aug 30;453(1):56–64.
   PubMed Web of Science ®Google Scholar
• Moschos SA, Usher L, Lindsay MA. Clinical potential of oligonucleotide-based therapeutics in the respiratory system. Pharmacol Ther. 2017 Jan;169:83–103.
   PubMed Web of Science ®Google Scholar
• Lee K, Jang B, Lee YR, et al. The cutting-edge technologies of siRNA delivery and their application in clinical trials. Arch Pharm Res. 2018 Sep;41(9):867–874.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ding L, Li Z, et al. Treatment of acute lung injury and early- and late-stage pulmonary fibrosis with combination emulsion siRNA polyplexes. J Control Release. 2019 Nov 28;314:12–24.
   PubMed Web of Science ®Google Scholar
• Biscans A, Coles A, Echeverria D, et al. The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo. J Control Release. 2019 May 28;302:116–125.
   PubMed Web of Science ®Google Scholar
• Park J, Park J, Pei Y, et al. Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines. Adv Drug Deliv Rev. 2016 Sep 1;104:93–109.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Meng Y, Zhao Y, et al. Toxicological exploration of peptide-based cationic liposomes in siRNA delivery. Colloids Surf B Biointerfaces. 2019 Jul 1;179:66–76.
   PubMed Web of Science ®Google Scholar
• Dokka S, Toledo D, Shi X, et al. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res. 2000 May;17(5):521–525.
   PubMed Web of Science ®Google Scholar
• Ma Z, Li J, He F, et al. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun. 2005 May 13;330(3):755–759.
   PubMed Web of Science ®Google Scholar
• Omidi Y, Barar J, Akhtar S. Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology. Curr Drug Deliv. 2005 Oct;2(4):429–441.
   PubMedGoogle Scholar
• Aqil F, Munagala R, Jeyabalan J, et al. Milk exosomes - Natural nanoparticles for siRNA delivery. Cancer Lett. 2019 May 1;449:186–195.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Takeshita F, Mizutani T, et al. A novel platform to enable inhaled naked RNAi medicine for lung cancer. Sci Rep. 2013 Nov 25;3(1):3325.
   PubMedGoogle Scholar
• Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011 Jun;37(6):1308–1331.
   PubMed Web of Science ®Google Scholar
• Fey RA, Templin MV, McDonald JD, et al. Local and systemic tolerability of a 2ʹO-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-alpha delivery by inhalation in mouse and monkey. Inhal Toxicol. 2014 Jul;26(8):452–463.
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001 May 01;411(6836):494–498.
   PubMed Web of Science ®Google Scholar